US2012058132A1PendingUtilityA1

Treatment of glycogen storage disease type II

59
Assignee: CHEN YUAN-TSONGPriority: Jul 18, 2000Filed: Mar 30, 2011Published: Mar 8, 2012
Est. expiryJul 18, 2020(expired)· nominal 20-yr term from priority
Inventors:Yuan-Tsong Chen
A61P 43/00A61P 9/02A61P 9/00A61P 37/06A61P 9/04A61P 3/10A61P 3/00A61P 21/00A61K 38/00A61K 38/47C12Y 302/0102A61K 45/06
59
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Methods of treating glycogen storage disease type II, by administering acid α-glucosidase, are described, as are compositions for use in treatment of glycogen storage disease type II.

Claims

exact text as granted — not AI-modified
What is claimed is: 
     
         1 . A method of treating glycogen storage disease type II in an individual, comprising administering to the individual a therapeutically effective amount of human acid α-glucosidase at a regular interval. 
     
     
         2 . The method of  claim 1 , wherein the glycogen storage disease type II is infantile glycogen storage disease type II. 
     
     
         3 . The method of  claim 1 , wherein the glycogen storage disease type II is juvenile glycogen storage disease type II. 
     
     
         4 . The method of  claim 1 , wherein the glycogen storage disease type II is adult-onset glycogen storage disease type II. 
     
     
         5 . The method of  claim 1 , wherein the therapeutically effective amount of human acid α-glucosidase is less than about 15 mg of acid α-glucosidase per kilogram of body weight of the individual. 
     
     
         6 . The method of  claim 5 , wherein the therapeutically effective amount of human acid α-glucosidase is about 1-10 mg of acid α-glucosidase per kilogram of body weight of the individual. 
     
     
         7 . The method of  claim 5 , wherein the therapeutically effective amount of human acid α-glucosidase is about 5 mg of acid α-glucosidase per kilogram of body weight of the individual. 
     
     
         8 . The method of  claim 1 , wherein the human acid α-glucosidase is recombinant human acid α-glucosidase. 
     
     
         9 . The method of  claim 1 , wherein the human acid α-glucosidase is a precursor of recombinant human acid α-glucosidase. 
     
     
         10 . The method of  claim 9 , wherein the recombinant human acid α-glucosidase is produced in Chinese hamster ovary cells. 
     
     
         11 . The method of  claim 1 , wherein the regular interval is monthly. 
     
     
         12 . The method of  claim 1 , wherein the regular interval is bimonthly. 
     
     
         13 . The method of  claim 1 , wherein the regular interval is weekly. 
     
     
         14 . The method of  claim 1 , wherein the regular interval is twice weekly. 
     
     
         15 . The method of  claim 1 , wherein the regular interval is daily. 
     
     
         16 . The method of  claim 1 , wherein the human acid α-glucosidase is administered intravenously. 
     
     
         17 . The method of  claim 1 , wherein the human acid α-glucosidase is administered intramuscularly. 
     
     
         18 . The method of  claim 1 , wherein the human acid α-glucosidase is administered intrathecally or intraventricularly. 
     
     
         19 . The method of  claim 1 , wherein the human acid α-glucosidase is administered in conjunction with an immunosuppressant. 
     
     
         20 . The method of  claim 19 , wherein the immunosuppressant is administered prior to any administration of human acid α-glucosidase to the individual. 
     
     
         21 . A method of treating cardiomyopathy associated with glycogen storage disease type II in an individual, comprising administering to the individual a therapeutically effective amount of human acid α-glucosidase at a regular interval. 
     
     
         22 . A pharmaceutical composition comprising human acid α-glucosidase in a container with a label containing instructions for administration of the composition for treatment of glycogen storage disease type II.

Join the waitlist — get patent alerts

Track US2012058132A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.